Supplementary Material

Title: Safety and Effectiveness of Adalimumab for the Treatment of Pyoderma Gangrenosum: A 52-Week Real-world Prospective Observational Study

Authors:

Toshiyuki Yamamoto[1], Hideaki Tanizaki[2], Kenshi Yamasaki[3], Naoko Matsubara[4], Masahiko Nakayama[4], Eri Iwashita[4], Keiichi Yamanaka[5]

Affiliations:

[1]Department of Dermatology, Fukushima Medical University, Fukushima, Japan

[2]Department of Dermatology, Kansai Medical University, Hirakata, Japan

[3]Department of Dermatology, Tohoku University, Sendai, Japan

[4]Medical, AbbVie GK, Tokyo, Japan

[5]Department of Dermatology, Mie University, Graduate School of Medicine, Tsu, Mie, Japan

Corresponding author:

Name: Naoko Matsubara, Ph.D.

E-mail address: naoko.matsubara@abbvie.com

Present address:

Kenshi Yamasaki, ALOOP CLINIC and LAB, Tokyo, Japan

Appendix

Study investigators:

Hideyuki Ujiie (Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan), Satoko Shimizu (Department of Dermatology, Sapporo City General Hospital, Sapporo, Japan), Yuji Kan (Department of Dermatology, Sapporo Medical University School of Medicine, Sapporo, Japan), Kuninori Hirosaki (Department of Dermatology, The Hokkaido Medical Center, Sapporo, Japan), Kenshi Yamasaki (Department of Dermatology, Tohoku University, Sendai, Japan), Tamihiro Kawakami (Department of Dermatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan), Michihiro Kono (Department of Dermatology and Plastic Surgery, Akita University Graduate School of Medicine, Akita, Japan), Takahiro Satoh (Department of Dermatology, National Defense Medical College, Tokorozawa, Japan), Kazumoto Katagiri (Department of Dermatology, Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama, Japan), Sei-ichiro Motegi (Department of Dermatology, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan), Eisaku Ogawa (Department of Dermatology, Shinshu University School of Medicine, Matsumoto, Japan), Hayakazu Sumida (Department of Dermatology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan), Akihiko Asahina (Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan), Shigeki Nagata (Department of Dermatology, Showa Medical University Koto Toyosu Hospital, Tokyo, Japan), Yayoi Tada (Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan), Yukari Okubo (Department of Dermatology, Tokyo Medical University, Tokyo, Japan), Keiko Tanaka (Department of Dermatology, Yamanashi Kosei Hospital, Yamanashi, Japan), Michiko Hirokado (Department of Dermatology, Yokohama Minami Kyosai Hospital, Yokohama, Japan), Takeshi Kambara (Department of Dermatology, Yokohama City University Medical

Center, Yokohama, Japan), Yoshihiro Kuwano (Department of Dermatology, Teikyo University Mizonokuchi Hospital, Kawasaki, Japan), Kentaro Matsumoto (Department of Dermatology, Shizuoka Saiseikai General Hospital, Shizuoka, Japan), Toshiharu Fujiyama (Department of Dermatology, Hamamatsu University School of Medicine, Hamamatsu, Japan), Masaki Otsuka (Department of Dermatology and Skin Oncology, Chutoen General Medical Center, Kakegawa, Japan), Hiroyuki Marusawa (Department of Gastroenterology and Hepatology, Japanese Red Cross Osaka Hospital, Osaka, Japan), Akihisa Yamamoto (Department of Dermatology, Takatsuki General Hospital, Takatsuki, Japan), Hideaki Tanizaki (Department of Dermatology, Kansai Medical University, Hirakata, Japan), Atsushi Otsuka (Department of Dermatology, Faculty of Medicine, Kindai University Hospital, Osaka, Japan), Satoru Shinkuma (Department of Dermatology, Nara Medical University, Kashihara, Japan), Hideya Takenaka (Department of Dermatology, Kyoto City Hospital, Kyoto, Japan), Fuminao Kanehisa (Department of Dermatology, Fukuchiyama City Hospital, Kyoto, Japan), Takashi Matsushita (Department of Dermatology, Faculty of Medicine, Pharmaceutical Health Sciences, Kanazawa University, Kanazawa, Japan), Kiyohiro Tsutsui (Department of Dermatology, Ishikawa Prefectural Central Hospital, Ishikawa, Japan), Makoto Shimizu (Department of Dermatology, Nagoya Medical Center, Aichi, Japan), Akimichi Morita (Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan), Keiichi Yamanaka (Department of Dermatology, Mie University, Graduate School of Medicine, Tsu, Mie, Japan), Hideki Kamiya (Department of Dermatology, Central Japan International Medical Center, Minokamo, Japan), Atsushi Fukunaga (Division of Dermatology, Department of Internal Related, Kobe University Graduate School of Medicine, Chuo-ku, Kobe, Japan), Kunitaro Fukuyama (Department of Dermatology, Kansai Rosai Hospital, Hyogo, Japan), Ken Washio (Department of Dermatology, Kobe City Nishi-

Kobe Medical Center, Hyogo, Japan), Sakae Kaneko (Department of Dermatology, Masuda Red Cross Hospital, Masuda, Shimane, Japan), Shin Morizane (Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan), Toshihisa Hamada (Department of Dermatology, Takamatsu Red Cross Hospital, Takamatsu, Japan), Yoshiko Morishita (Department of Dermatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan), Haruna Yoshioka (Dermatology, Japan Community Healthcare Organization Kyushu Hospital, Kiyakyushu, Japan), Natsuko Saito-Sasaki (Dermatology, University of Occupational and Environmental Health, Kitakyushu, Japan), Keiko Hashikawa (Department of Dermatology, Kurume University School of Medicine, Kurume, Fukuoka, Japan), Takeshi Nakahara (Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan), Hiromichi Takeshita (Dermatology Unit, Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan), Tsuyoshi Awazawa (Department of Dermatology, Naha City Hospital, Okinawa, Japan), Takuya Omine (Department of Dermatology, Graduate School of Medicine, University of the Ryukyus, Nishihara, Japan), Kaoru Sakieda (Department of Dermatology, Okinawa Kyodo Hospital, Okinawa, Japan), Jun Aoi (Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan), Rieko Nemoto (Department of Dermatology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan), Atsunori Baba (Department of Dermatology, Kagoshima City Hospital, Kagoshima, Japan)

Table S1. Concomitant doses of systemic steroids at each observation time point (median prednisolone-equivalent dose mg/day)

Time point	n	Concomitant systemic steroids, n (%)	Mean (mg/day)	SD	Median	Range
At treatment initiation[a]	67	39 (58.2)	23.3	13.1	20.0	2.0–60.0
Week 12	53	29 (54.7)	18.6	11.9	20.0	2.0–45.0
Week 26	46	25 (54.3)	17.8	12.1	17.5	1.0–45.0
Week 52	29	15 (51.7)	19.7	13.4	20.0	2.0–45.0
At treatment discontinuation	38	14 (36.8)	18.1	9.5	17.5	5.0–30.0

[a]Including one patient who started concomitant systemic steroid use on the same day as the start of adalimumab treatment

Table S2. Proportion of patients with a PGA (total lesions) score of 0/1 and 0 at weeks 12, 26, and 52 and at treatment discontinuation (LOCF)

Time point	N	PGA score 0/1	95% CI	PGA score 0	95% CI
Week 12	54	18 (33.3)	21.1–47.5	12 (22.2)	12.0–35.6
Week 26	55	24 (43.6)	30.3–57.7	15 (27.3)	16.1–41.0
Week 52	56	31 (55.4)	41.5–68.7	20 (35.7)	23.4–49.6
At treatment discontinuation	29	15 (51.7)	32.5–70.6	13 (44.8)	26.4–64.3

Values are presented as N and n (%).

CI, confidence interval; LOCF, last observation carried forward; PGA, Physician Global Assessment.

Table S3. Proportion of patients with a PGA (target lesion) score of 0/1 and 0 at weeks 12, 26, and 52 and at treatment discontinuation (LOCF)

Time point	N	PGA score 0/1	95% CI	PGA score 0	95% CI
Week 12	55	18 (32.7)	20.7–46.7	12 (21.8)	11.8–35.0
Week 26	56	25 (44.6)	31.3–58.5	16 (28.6)	17.3–42.2
Week 52	57	33 (57.9)	44.1–70.9	22 (38.6)	26.0–52.4
At treatment discontinuation	30	16 (53.3)	34.3–71.7	14 (46.7)	28.3–65.7

Values are presented as n (%) or n.

CI, confidence interval; LOCF, last observation carried forward; PGA, Physician Global Assessment.

Table S4. Proportion of patients with an IIA score of 0 at weeks 0, 12, 26, and 52 and at treatment discontinuation (LOCF) for (a) erythema and (b) border elevation

(a)

Time point	N	IIA score 0	95% CI
Week 0	54	6 (11.1)	4.2–22.6
Week 12	58	22 (37.9)	25.5–51.6
Week 26	59	25 (42.4)	29.6–55.9
Week 52	60	30 (50.0)	36.8–63.2
At treatment discontinuation	29	15 (51.7)	32.5–70.6

(b)

Time point	N	IIA score 0	95% CI
Week 0	54	3 (5.6)	1.2–15.4
Week 12	58	23 (39.7)	27.0–53.4
Week 26	59	28 (47.5)	34.3–60.9
Week 52	60	32 (53.3)	40.0–66.3
At treatment discontinuation	29	19 (65.5)	45.7–82.1

Values are presented as n (%) or n.

CI, confidence interval; IIA, Investigator Inflammation Assessment; LOCF, last observation carried forward.

Table S5. VRS scores at weeks 0, 26, and 52 and at treatment discontinuation (LOCF)

VRS score	Week 0	Week 26	Week 52	At treatment discontinuation
n	52	52	54	23
0	3 (5.8)	21 (40.4)	25 (46.3)	14 (60.9)
1	15 (28.8)	19 (36.5)	19 (35.2)	4 (17.4)
2	21 (40.4)	10 (19.2)	8 (14.8)	4 (17.4)
3	13 (25.0)	2 (3.8)	2 (3.7)	1 (4.3)

Values are presented as n (%) or n.

LOCF, last observation carried forward; VRS, Verbal Rating Scale.